Therapeutic perspective on vascular cognitive impairment

• Published in: Pharmacological research Vol. 146; p. 104266
• Main Authors: Toyama, Kensuke, Spin, Joshua M., Mogi, Masaki, Tsao, Philip S.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 01.08.2019
• Subjects: Animals; Blood-Brain barrier; Cognitive Dysfunction - genetics; Cognitive Dysfunction - therapy; Dementia, Vascular - genetics; Dementia, Vascular - therapy; Humans; microRNA; MicroRNAs; Tight Junctions; Vascular cognitive impairment; MCI; BBB; ZO-1; Vascular cognitive impairment; miR; WML; Blood-Brain barrier; VaD; microRNA; mRNA; VCI; LNA
• ISSN: 1043-6618; 1096-1186
• DOI: 10.1016/j.phrs.2019.104266

[Display omitted] Dementia is one of the greatest public health concerns for the modern aging world. Over the last decade, most researchers developing new therapeutic strategies for dementia have focused on amyloid-β. In contrast, numerous recent studies have indicated that vascular risk factors are associated with various forms of dementia, and that in fact most forms of dementia can be considered an extension of vascular disease. Accordingly, it is sensible to pursue treatment approaches that focus on the blood vessels. Blood-brain barrier (BBB) disruptions in the white matter of patients with vascular cognitive impairment (VCI) have been observed using imaging analysis, and might be potential targets for novel VCI treatment. Tight junctions between cerebral endothelial cells play an important role in the function of the BBB, and recent studies have demonstrated the essential role of microRNAs in regulating tight junctions. Further elucidation of the mechanisms of tight junction-disruption in dementia are likely to lead to promising novel treatments. In this article, we summarize current knowledge regarding microRNAs and vascular cognitive impairment and the possibility of utilizing microRNAs as biomarkers for BBB dysfunction, and seek to envision future therapeutic strategies.